Gene modulation is now more flexible and accessible thanks to Horizon's new CRISPRmod CRISPRi portfolio. The system leverages an inactive Cas9 complex to block transcription resulting in precision targeted gene down regulation. Read more about our newest offering:
A review of two studies demonstrating that large-scale pooled base editor screens can separate pathogenic from benign mutations and identify variants that are associated with altered cellular growth or response to DNA-damaging agents.
We’re happy to discuss your project in English, French, German, Italian, or Spanish; and have teams in both the US and Europe to provide flexible service hours.
The promise of base editing showcases the ingenuity of scientists in their inexorable quest to precisely and safely engineer the genome.
Review of publications using HAP1 cells to set up validation assays beyond the typical western blot.
Our top 5 tips for working with HAP1 cells.
A summary of a recent publication in The Journal of Biotechniques showing the utility of Horizon's synthetic sgRNA for CRISPR mediated transcriptional activation studies.
Can base editing move cancer cell therapy further towards off-the-shelf treatments?
Horizon's new Cell free DNA formulated in synthetic matrix reference offers greater compatibility with commonly used cfDNA extraction kits.
Liquid biopsy holds many advantages over solid tumor testing of cancer patients. It is less invasive for the patient, avoiding the need for surgical biopsy, and has improved levels of sensitivity to detect low frequency somatic driver mutations.